Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29060701 | 0.95 | SLC6A2 (0.40) | PRCPDPP7TLR2MAPTSLC6A2 | |
| SCHEMBL16774368 | 0.85 | SOAT1 (0.45) | PRCPDPP7TLR2SCN4ASLC6A2 | |
| SCHEMBL25413989 | 0.85 | SOAT1 (0.45) | PRCPDPP7TLR2SCN4ASLC6A2 | |
| SCHEMBL3330660 | 0.84 | PRCP (0.45) | PRCPDPP7SCN4ASLC6A2SLC6A3 | |
| SCHEMBL10829027 | 0.84 | PRCP (0.45) | PRCPDPP7SCN4ASLC6A2SLC6A3 | |
| SCHEMBL133135 | 0.84 | PRCP (0.45) | PRCPDPP7SCN4ASLC6A2SLC6A3 | |
| SCHEMBL115996 | 0.84 | PRCP (0.45) | PRCPDPP7SCN4ASLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL133134 | 0.83 | PRCP (0.44) | PRCPDPP7TLR2MAPTSCN4A | |
| Hydrochloric Acid SCHEMBL3530351 | 0.83 | PRCP (0.44) | PRCPDPP7TLR2MAPTSCN4A | |
| Ammonia Solution, Strong SCHEMBL6516951 | 0.83 | PRCP (0.44) | PRCPDPP7SCN4ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759109-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| CN-111788204-B | Substituted pyrrolizine compounds as inhibitors of HBV replication | 吉利德科学公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11420974-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3759109-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| CN-111788204-A | Substituted pyrrolizine compounds as inhibitors of HBV replication | 吉利德科学公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2019-09-26 | — | — | US | disclosed |
| WO-2019165374-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | PRCP 974/4885DPP7 1061/4885TLR2 3551/4885 |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | PRCP 974/4885DPP7 1061/4885TLR2 3551/4885 |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | PRCP 974/4885DPP7 1061/4885TLR2 3551/4885 |
| US-11420974-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | PRCP 974/4885DPP7 1061/4885TLR2 3551/4885 |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | PRCP 974/4885DPP7 1061/4885TLR2 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.